HUMAN ALBUMIN THERAPY OF ACUTE ISCHEMIC STROKE

Medicine & Life Sciences

1. Stroke 100%
2. Human Serum Albumin 91%
3. Albumins 88%
4. Neuroprotection 29%
5. Therapeutics 20%
6. Clinical Trials 17%
7. Standard of Care 17%
8. Canada 15%
9. National Institute of Neurological Disorders and Stroke (U.S.) 15%
10. Multicenter Studies 13%
11. Biometry 12%
12. Placebos 12%
13. Data Management 12%
14. Maximum Tolerated Dose 10%
15. Intracranial Hemorrhages 10%
16. Phase III Clinical Trials 10%
17. Brain Injuries 9%
18. Tissue Plasminogen Activator 9%
19. Cerebral Infarction 9%
20. Neuroprotective Agents 9%
21. Brain Ischemia 9%
22. Traumatic Brain Injury 9%
23. Intravenous Administration 8%
24. Teaching Hospitals 8%
25. Random Allocation 8%
26. Echocardiography 7%
27. Infarction 7%
28. Epidemiology 7%
29. University Hospitals 7%
30. Safety 6%
31. Heart Failure 6%
32. Animal Models 6%
33. Hypertension 6%